

Index

Note: MDPTs - multidisciplinary prescribing teams

Page numbers in *italics* refer to figures, whilst those in **bold** refer to tables.

- abbreviations in prescriptions 55–56, **57**
- abdomen, quadrants **228**
- abdominal examination 221–222, 226, **227–228**
- abortions 254
- absorption of drugs 149, *151*, 151–152
 - breastfeeding and 256
 - children/young people 262–263
 - dosage forms 152
 - liver disease 243
 - older people 258
 - pregnancy **252**
 - renal impairment 248
 - routes *151*, 151–152, 152–153
- Access to Health Records Act (1990) **75**
- Access to Medical Reports Act (1988) **75**
- accident and emergency department 311
- accidents 261
- accountability 40, 117, 288
- acetylcholine 160
 - receptors 157, 158
- acetylcholinesterase inhibitors 160
- Act of Parliament 47, 48, 88
- actus reus 49
- acute care, prescribing errors 285
- adherence 176, 260
 - see also* concordance
- administration routes of drugs *151*, 151–152, 152–153
 - breastfeeding 256
 - children 262–263, 265
- Adults with Incapacity (Scotland) Act (2000) 71–72
- advance directives 72, 73, 80
- adverse drug reactions (ADRs) 149, 170
 - breastfeeding 172, 255, 256
 - cessation 173
 - children 265
 - consequences 170, 171
 - costs relating to 149
 - disease states 171, 172
 - ethnicity 172
 - gender 172
 - influencing factors 171–172
 - liver impairment 171
 - management and avoidance 169–174
 - MHRA e-learning 174
 - MHRA monitoring 38
 - multiple drug therapy 171–172
 - older people 171, 172, 258
 - renal impairment 171
 - reporting 173
 - side effects vs 170
 - steps to determine cause 172–173
 - unlicensed medicines 54
 - see also* side effects
- advertising by drug companies 105, 106–107
- Advisory Committee on Borderline Substances (ACBS) 54
- advocacy 72–73, 267
- affinity 156

- age
 breathing rates 208, **208**
 childhood stages **262**
 pulse rate **212**
 renal function decline 166, 167, 258
see also older people
- ageing workforce 286–287
- agonists 156–157, 157
- Airedale NHS Trust v Bland* (1993) 82
- albumin 242, 248
- alcohol 167, 256
- allergies **131**, 172
- 'allied health professional prescriber' 2
- allied health professionals 24–27
 accountability and responsibility 40
 benefits of prescribing 90
 educational programmes 29
 independent prescribing 190
 MDPTs 190
 negligence and duty of care 51
 number 279
 prescribing history 278
 professional code of practice 39, **39**
 supplementary prescribing 190
 training 190
- Allied Health Professions Medicines Project 25
- Alzheimer's disease 72
- angiotensin-converting enzyme (ACE)
 inhibitors 160, 171, 249
- angiotensin II 160
- annual development review 291
- antagonists 157, 158, 167
- antibiotics 211
- antidepressants 159, 170, 245, 259
- antihistamines 158, 245, 246
- antihypertensives 163, 167, 168
- antimuscarinic drugs 158, 170
- antipsychotics 245
- apex beat 212
- appraisal 297–298
- Area Prescribing Committee (APC) 298
- arthritis 193
 case studies 173, 306
- ascites 244, 245
- assessment(s)
 breathing 207–209
 independent prescribing 12–14
 mental capacity 58, 68–69
 pain in children 215
 renal function 247–248
 of risk 76–77
- Association of the British Pharmaceutical Industry (ABPI) 105, 106
- asthma 150, 170, 208, 209, **210**
 case study 308
 remote prescribing 44
- attitude shifts 3–4
- audit of practice 292
- auditory acuity 219
- auroscope use 218–219
- auscultation 217
 abdomen **227**
 respiratory system **224**
- autonomy 58–77, 69
 definition 59–61, 79
 deontology and 65
 informed consent and 63–64, 65, 66
 Kantian view 60, 66
 media influence 107
 respect for 79
 uninformed consent 63–64
 young people 69
- AVPU scale 206, 207, **207**
- B (Ms) v An NHS Trust* (2002) 67
- Balint's consultation model 124
- Battle's sign **219**
- behaviour, health beliefs and 101
- bendroflumethiazide 168
- beneficence 79
- benefits, non-medical prescribing 3, 4, 13, 89–90,
 185–188, 283
- benzodiazepines 158, 167
- Berne's model of consultation 125
- 'best interest' decision/principle 59, 68, 72, 73,
 80–81
 autonomy and 60, 61
 children and 65, 69, 70
- beta blockers 150, 158
- bilirubin 242
- bioavailability 152–153
 liver disease 243–244
 renal impairment 248
- biomechanics 193
- black and minority ethnic (BME) groups
 269–271, **270**
- bleeding risk, drugs increasing 245, **245**
- blood clotting, reduced, in liver disease 242, 245
- blood pressure 213
 elevated *see* hypertension
 measurement 213, **213, 214**
- body language 119, **120**

- body surface area (BSA) 247, 263
 Bolam test 50–51
Bolam v Friern Hospital Management Committee (1957) 50–51
 borderline substances 54
 Botox® 9, 44
 bowel sounds **227**
 brachial artery, pulse 212
Bradshaw's Taxonomy of Needs (1972) 10
 bradycardia **212**
 bradypnoea 208
 breastfeeding 255–257
 case study 169, 308
 holistic approach 257
 prescribing considerations **257**
 breast milk 255–256, 257
 breathing assessment 207–209
 breathing problems 150, 208
 breath sounds **225**
 adventitious **226**
 British Medical Association (BMA) 69, 71, 72, 77
British National Formulary (BNF) 20, 103, 165
 ADRs/side effects 170, 172
 breastfeeding 256, 257
 controlled drugs 58
 influence on prescribing 103
 liver disease 153, 243, 245
 MDPTs 183
 medicine interactions 154, 159, 167
 narrow therapeutic index drugs 175
 numeracy skills and dosages 234
 pregnancy 253, 254
 prescription writing 52, **56**
 renal impairment and 247, 248
British National Formulary for Children (BNFC) 103, 263, 264
 bruits **227**
- calculation skills 234, 235
 Caldicott guardians 74
 Calgary–Cambridge guide model (Kurtz) 116, 125, 126
 Canada 281
 capacity *see* mental capacity
 captopril 160
 carbamazepine 172
 care homes 58, 236
 Care Quality Commission (CQC) 58, 289, 290
 Care Quality Commission (Registration) Regulations (2009) 289
- care regulators 45, **45**
 carotid artery 212
 carrier molecules 157, 159
 examples of drug action **161–162**
 case law 47, 64
 table of cases 84
 case studies xvii
 health professional 23–24, 310–314
 independent prescribing 24, 25
 MDPTs 199, 313
 patient 305–309
 supplementary prescribing 23–24
 V100, V150, V300 20, 21, 22
 cerebral vascular disease 261
Chatterton v Gerson (1981) 64
 chemotherapy, MDPT for 196
Chester v Afshar (2005) 51, 65
 Children Act (1989) 70, 268
 Children Act (2004) 268
 children and young people 20, 262–268
 administering medicines to 268
 advocacy 73
 autonomy 59, 61
 capacity to consent 70
 case studies 308
 communication 122, 267
 consent 65, 69–71
 consultations 122, **123**, 267
 defined 262, **262**
 drugs licensed for 256
 health beliefs, health profile 267
 history taking 266–267
 holistic approach to prescribing 266–268
 licensing of drugs 264
 mental health issues 267
 pain assessment 215
 podiatry 193
 prescribing considerations 264, 265, **265**, 268
 professional responsibilities towards 266
 pulse rate **212**
 safeguarding 268
 school nurses and 20
 transcribing for 46
 unlicensed medicines 264
 welfare and overriding lack of consent 70, 71
 chiropodists *see* podiatrists
 ciprofloxacin 164
 civil claims 41
 civil law 49, 49, 50
 clarithromycin 171

- clinical audit 293
- clinical commission group (CCG) 284
- clinical decision-making (CDM) 138–144
 - advance directives 72
 - advocacy 73
 - autonomy and 60–61, 69
 - 'best interest' *see* 'best interest' decision/principle
 - biases 143
 - children 71, 72
 - cognitive continuum 138–139, 141
 - complexity 97
 - consultations 114, 125, 126, 138–144
 - dynamic nature of 138, 139–140, 143
 - ethics 77, 78
 - factors influencing 139, 143
 - heuristics and intuition 141–142, 143
 - hypothetical–deductive model 139–140, 141, 144
 - independent prescribing 13–14
 - legal issues 42
 - medical and non-medical prescribers 138
 - monitoring/follow-up 137
 - numeracy 234
 - paternalism 59, 60
 - patient involvement 117, 176
 - pattern recognition 140–141, 143, 144
 - personal beliefs/preferences 91
 - product choice and 104
 - shared, informed consent and 66
 - strategies 139, 143
 - tort law and 50
- clinical examination 135–136, 205, 216–218, 237
 - abdominal 221–222, 226, **227–228**
 - ENT system 206, 218–220
 - neurological 229–232
 - principles 216–218
 - respiratory system 220–221, **223–224**
- clinical governance 8, 40, 42, 288–293
 - accountability 40, 288
 - annual reports 288
 - appraisal 297–298
 - clinical audit 293
 - CPD 294–297
 - formularies strengthening 104
 - framework 291–293
 - introduction/background 288
 - NHS Plan* aims 290
 - as 'organisational conscience' 290
 - remote prescribing 45
 - seven key pillars 288
 - trust structures to support 288–289
- clinical guidelines 294
- clinical management plan (CMP) 15–17, 19, 136–137
 - agreement on 16
 - allied health professionals 17, 18, 19, 24–25
 - case study 312
 - consent 63, 71
 - description and information included 15–16, **16**
 - handover, consultation model 125
 - independent prescriber responsibility 15, 16
 - limitations/problems affecting 284
 - negotiation 117, 136
 - nurses 17
 - pharmacists 17, 23, 24
 - review 17
 - supplementary prescribing 15, 16–17, 18
 - termination 17, **17**
- clinical negligence 41, 51
- clinical practice changes 6–7
- clinical reasoning *see* clinical decision-making (CDM)
- clinical skills 136, 205–239
- clinical supervision 292, 297
- clinical trials 173, 264
- 'close communication' 108
- clotting, reduced, in liver disease 242, 245
- codeine 170, 172
- codes of conduct 95
- codes of practice 39, **39**, 95
- cognitive continuum 138–139, 141
- collaborative working practice 200
- commissioning, MDPTs and 197–199
- Commissioning for Quality and Innovation (CQUIN) 290
- common law 47
- communication
 - children/young people 122, 267
 - MDPTs 108, 195, 195–196, 198
 - therapeutic, consultations *see* therapeutic communication
- community care 286
- community nurses xiv, 21, 135
 - ageing workforce and 286
 - case study 311
 - education needs 21
 - impact of prescribing 284
- Community Practitioner Nurse Prescriber Formulary 20, 162, 166
- community practitioner nurses 20, 21, 90
- co-morbidity 166
- controlled drugs **53**

- formularies 20, 162, 166
- influence on prescribing 89–90
- transcribing 45
- co-morbidity 165–167
 - case study 306
 - narrow therapeutic index drugs 175
 - pharmacology 165–166
 - polypharmacy 166–167, 171–172
- ‘comparative need’ 10–11
- compensation 51, 52
- competence 20
 - maintaining 296–297
 - prescribing for children 266
 - summaries/considerations 30–31, 83, 110, 145, 180, 202–203, 238–239, 272, 299
- competency framework 6, 296
- compliance 136, 176
- concordance 11, 103, 136, 175–176, **177**
 - older people 261
 - patient influence on prescribing 176
- conduct, professional standards 39, **39**
- confidence of prescribers 104
- confidentiality 74–75, **75**, 186
 - children/young people 267–268
- confusion, drugs causing 245
- conscious level 206–207
- consent 58–77
 - adults lacking mental capacity 65, 67–69, 71–72
 - adults with mental capacity 62–66
 - advance directives 72
 - autonomy and 63–64, 65, 66, 79
 - avoiding litigation 76, 76–77
 - children 20, 65, 69–71
 - complexity of obtaining 64, 65
 - definition 61
 - England, Wales, Scotland, N. Ireland 71–72
 - explicit (‘express’) verbal 62
 - explicit (‘express’) written 63
 - ‘Fraser competent’/guidelines 70
 - ‘Gillick competent’ 70
 - implied 62
 - importance 61–77
 - information for 66
 - informed 63–66
 - lasting power of attorney (LPA) 71–72
 - mental capacity to/for 61, 62–66
 - ‘misinformed’ 66
 - non-verbal 62
 - parents 70
 - remote prescribing 44
 - school nurses 20
 - side effects and 64
 - standards of disclosure for 65
 - ‘un-informed’ 63, 64
 - withdrawal 64–65
 - young people (16,17 years) 69, 70
- consequentialism 78
- constipation 152, 165, 170, 246
- consultations 96–97, 98, 113–147
 - children 122, **123**, 267
 - clinical decision-making 125, 126, 138–144
 - communication in *see* therapeutic communication
 - conclusion 137
 - definitions/use of term 114
 - as dynamic journey 125
 - effective 113–147
 - health beliefs and 101
 - influence on prescribing 96–97, 98
 - models 114, 116, 124–126
 - older people 122, 124
 - parts of 121
 - patient expectations 97–98
 - patient satisfaction 283
 - time, organisational issues 94–95, 283, 284
 - time before collecting patient 121–122
 - young people 122
- consultation umbrella 113, 114–115, 115, 126–138, 139, 144
 - consultation conclusion 137
 - follow-up 137
 - history taking *see* history taking
 - physical examination 135–136
 - plan/treatment 136–137
 - tests and investigations 136
- consumers, patients as 98–99
- contact professional of MDPT 199
- continuing professional development (CPD) 186–187, 294–296, 298
 - considerations 30–31, 83, 110, 145, 180, 202, 238–239, 272, 294, 299
 - evidence-based resources 295
 - funding 95–96
 - importance 295, 296
 - maintaining competency and 296–297
 - MDPTs 186–187
 - methods/ways of achieving 295
 - provision 292
 - take-up 296
- continuity of care 94
- contraception 244, 254

- controlled drugs **38**
 allied health professionals 18, 25, **53**
 legal issues 43, 46, 58
 nurses 22, **53**
 pharmacists 23, 24, **53**
 prescribing 58
 prescribing rights **53**
 stolen prescription forms 46
 supplementary prescribing 18, 23, 25
 transcribing and 46
 V300 prescribing 22
- core themes, in book xv
 core values (six) 7
 coronary heart disease 261
 Coroners Act (1988) 81
 cosmetic injectables 9, 44–45
 cost-effectiveness 7, 8, 103, 199
 MDPTs 199
 PACT data 284, 294
 product choice/formularies 103, 174, 294, 298
- courts 48
- cranial nerve examination 229, **230**
 checklist **231–232**
- creatinine clearance (CrCl) 247
- crime and criminal law 49, 49
- criminal behaviour 43
Crown Report (1989) xiv
Crown Report (1999) xiv, **3**
- 6 Cs 7
- culture
 influencing prescribing 99–101
 organisational 93
- current health, in history taking **129**
- current practices 277–278
- customary law 47
- cyclosporin 174
- cytochrome P450 enzymes 154, **154**, 175
- Darzi review 200
- data protection 74–75, **75**
- Data Protection Act (1998) **75**
- death, doctrine of double effect 81–82
- decision-making *see* clinical decision-making (CDM)
- deep tendon reflexes 229, **233**
- definition, non-medical prescribing 2
- dementia 72, 261
- dentists 15, 27, 37, 44, 52
- deontology 65, 78
- Department of Health (DH) 6, 67–68, 74–75
 Operating Framework 6
- ‘dependent prescribing’ 14
- depression 246
 case study 307
- dermatology services 283, 310
- diabetes 44, 168
 case studies 305, 314
- diabetic neuropathy 164
- diagnosis 126, 135, 280
- diarrhoea 150, 152, 170, 248
- diastolic pressure 213
- diethylstilbestrol 251
- digoxin 171, 174, 175
- disclosure of information 65, 74
- dispensing errors 76
- disposal of medicines 260
- distribution of drugs 20, 153, 167
 children/young people 263
 liver disease 244
 older people 258
 pregnancy **252**
 renal impairment 248
- district nurses xiv, 20, 277
 benefits of prescribing 90
 changing roles 21
 MDPTs 194
- diuretics 259
- doctors
 impact of non-medical prescribing 282
 junior 4, 6
 prescribing errors 4, 285
- doctrine of double effect (DDE) 81–82
- documentation 94–95
Donoghue v Stevenson (1932) 50
- ‘do no harm’ 79–80
- dosage(s)
 children/young people 263
 older people 260
 renal impairment 247, 248, 249–250
- dosage form 152
- dose–response ‘ceiling’ effect 167
- doxazosin 170
- drug classification 37, **38**
- drug companies, influence on prescribing 105–107, 199
- drug costs, NHS 7, 105, 177, 199, 296
 cost-effective prescribing 103, 174, 294, 298
- drug-dependency 61
- drug history (DH) **130–131**
- drug–illness interactions 167
- drug interactions
 examples 164, 171, 244

- management and avoidance
 - 167–169
- narrow therapeutic index drugs 175
- oral contraceptives 244
- pharmacodynamic 167
- pharmacokinetic 168
- polypharmacy 167, 171
- protein-bound drugs 153
- drug promotion 106
- drug–protein complex 153, 244
- Drug Tariff 53
- duloxetine 164–165
- duty of care 50–52, 78, 97
 - breaches 50
- dyspnoea 208–209
- Dysport® 44

- ear, nose and throat system *see* ENT system
- ears, examination 218–219, **219**
- EASE mnemonic xvi
- economics and funding 7–8, 92–93, 298
 - cost savings of non-medical prescribing 284, 298
 - CPD 95–96
 - drug costs *see* drug costs, NHS
 - local formularies 104
 - long-term conditions and 149
 - R&D costs 106
 - see also* cost-effectiveness
- education/education programmes 4
 - access to 27–29
 - adverse drug reactions 174
 - ageing workforce 286
 - allied health professionals 29
 - consent 66
 - criteria for access 28
 - to diagnose 280
 - inadequacy of courses 36
 - independent prescribing 13
 - infrastructures 287
 - MDPTs **188**, 200, 201
 - NPC prescribing pyramid 58–59
 - nurses 19, 20, 21, 28, 286
 - optometrists 26, 29, 192
 - other countries 280
 - patient/family, specific drugs 164–165
 - pharmacists 29, 188
 - standards 28
 - supplementary prescribing 17
 - uptake of courses 278
 - V100 19, 20, 21
 - V150 21, 286
 - V300 21–22, 286
- efficacy, non-medical prescribing 4–5
- ego states 125
- E-Learning for Health Care (2014) 5
- elimination of drugs *see* excretion of drugs
- emergency supply requests 54
- employers, vicarious liability 41–42
- employment contracts 42
- end-of-life care 73, 81–82
- enterohepatic circulation 244
- ENT system 206
 - examination 218–220, **219**, **220**
- enzyme(s) 156–160, 244
 - examples of drug action **161–162**
 - induction/inhibition 154, 175
- epilepsy 58, 251, 253
- EQUIP study 236
- errors 4
 - dispensing 76
 - medication 76, 178, 235
 - numeracy skills 285
 - prescribing *see* prescribing errors
- erythromycin 170, 171
- estimated glomerular filtration rate (eGFR) 247
- ethics 35–88, 77–82
 - autonomy 60, 79
 - 'best interest' *see* 'best interest' decision/principle
 - components 77
 - confidentiality 74
 - consent 64–65
 - definition 77
 - dilemmas 78
 - doctrine of double effect 81–82
 - drug companies 106
 - group/personal 77, 78
 - philosophical 77, 78
 - principles 79–80
 - professional 78
 - respect for persons 80
 - theories 78–79
 - virtue 79
 - withdrawal of consent 64–65
- ethinyloestradiol 244
- ethnic factors/ethnicity 99, 100, 172
- ethnic groups 269–271
- European Convention of Human Rights and Biomedicine (1997) 64, 65
- European Law 48
- evidence-based practice 42–43, 96, 98, 104

- evidence-based resources, CPD 295
- excipients 265, **265**
- excretion of drugs 155, 166, 247
- breastfeeding and 256
 - children/young people 263
 - liver disease 244
 - older people 258
 - pregnancy **252**
 - renal impairment 166, 167, 171, 247, 249
- expectations of patients 10–11, 97–98, 99, 107, 136
- 'expressed need' 10
- FACECARES mnemonic 176, **177**
- falls 261
- families, involvement in MDPTs 194, 197
- family advocates 73
- Family Law Reform Act (1969) 69, 70
- family surrogates 73
- fatalism 102
- 'felt need' 10
- fertility 254
- fever 210
- Fifth Report (2004) 43
- 'fifth vital sign' 214
- first-pass metabolism/effect 153, 243
- flucloxacillin 172
- folic acid 254
- follow-up 137
- formularies 103–104
- building/developing 160–165
 - Community Practitioner Nurse Prescriber 20, 162, 166
 - impact on prescribing 103–104
 - local 8, 104, 294
 - nurse prescribers' xiv, 20, 162
 - nurse prescribers' extended xiv, 11, 22, 278
 - personal 104, 160–165, 234, 253
 - see also *British National Formulary* (BNF)
- formulation of drugs, for children 264
- Fourth Report (2004) 43
- Francis Report 36
- 'Fraser competent'/guidelines 70–71
- fraud 43
- Freedom of Information Act (2000) **75**
- Freedom to Speak Up Review 43
- friction rub **227**
- γ -aminobutyric acid (GABA), GABA receptors 158
- gastric emptying 149, 150, 152, 262
- gender, prescribing for 269
- adverse drug reactions 172
- General Medical Council (GMC) 44, 62, 63, 236
- General Optical Council (GOC) 26, 28, 192
- General Pharmaceutical Council (GPhC) 2, 5, 23, 25, 28, 40, 188
- consent and 62
 - shared decision-making 66
- general sales list (GSL) medicines 37
- generic medicines 174, 298
- gentamicin 244, 248
- 'Gillick competent' 70
- Gillick v West Norfolk and Wisbech Area Health Authority* (1985) 70
- Glasgow coma scale (GCS) 206, 207, **207**
- glomerular filtration rate (GFR) 247
- glucose-6-phosphate dehydrogenase (G6PDH) deficiency 172
- glucuronides 248
- good practice guidance 178, 237
- 'good prescribing' 149, 178
- governance 40
- GPs, impact of non-medical prescribing on 282
- gypsies 271
- H₂ receptor antagonists 158
- half-life of drugs 155–156, **156**, 256
- harm, reducing 76–77
- Health and Care Professions Council (HCPC) 2, 3, 24, 25, 28, 40
- Health and Social Care Act (2001) xiv
- Health and Social Care Act (2008) 289
- Health and Social Care Act (Regulated Activities) Regulations 2009 289
- health beliefs 101
- models 101–102
 - young people 267
- Health Care and Associated Professions (Indemnity Arrangements) Order 2014 40–41
- Healthcare Quality Improvement Partnership (HQIP) 293
- Health Education England 4, 287
- health professional case studies 310–314
- Health Professions Council (HPC) 191, 192, 193
- health promotion 10, 13, 90
- health psychology 101
- health status
- black and minority ethnic groups 270, **270**
 - gypsies and travellers 271
- health visitors xiv, 20, 22
- case study 310
 - education programmes 22, 28
- heart rate **212**

- hepatic encephalopathy 245–246
 hepatotoxicity 171
 heuristics 141–142
 histamine H₂ receptor blockers 158
 history (of non-medical prescribing) 1–2, 3, 277, **278**, 278–280
 history of presenting complaint (HPC) **128–129**
 history taking 126–135, 216
 aide memoire **127**
 children 266–267
 elements in 127, **127**, **128–134**
 illustration 127, **128–134**, 134
 pregnancy 253
 remote prescribing 44
 HIV infection 172
 holistic approach xv, 7, 11, 100
 BME groups 270
 breastfeeding 257
 children/young people 266–268
 in co-morbidity 166
 liver disease 246, **247**
 MDPTs 194
 older people 260–261, **261**
 pregnancy 254, **255**
 renal impairment 250, **250**
 hospital admission, drug-related 178, 236, 258
 hospital care *see* secondary (hospital) care
 Human Rights Act (1998) 64, **75**
 hyoscine 170
 hyperkalaemia 249
 hypertension 160, 163, 164, 167, 168
 case studies 307, 308
 medicine management 177
 hypnotics 245, 259
 hypothetical–deductive model 139–140, 141, 144
 hypoxia 209

 idiosyncratic reactions 171
 immunisation 27, 108
 impact of prescribing 281–284
 on doctors 282
 organisational 283–284
 on patients 282–283
 on prescribers 281–282
 impression, in history taking **134**
 indapamide 163, 167
 independent prescribers, definition 14
 independent prescribing xiv, 6, 12–14
 allied health professionals 190
 assessment 12–14
 case studies 24, 25
 clinical decision-making 13–14
 controlled drugs **53**
 definition 12, 14, 22
 education 13
 factors preventing/limiting 283–284
 health professional requirements 14
 increase in 18
 MDPTs 189, 190, 191, 192
 nurses **53**, 90
 optometrists 26, **53**, 192
 pharmacists 23, 24, **53**, 189
 physiotherapists 25, 191
 podiatrists 25, 193
 radiographers 191–192
 supplementary prescribing vs 11–19
 undiagnosed conditions 12, 13
 V300 and 21–22
 infection, detecting/monitoring for 210, 213
 information
 access, for patient safety 94, 96–97
 disclosure 65, 74
 for informed consent 66
 MDPTs 186
 patient expectations based on 98
 from pharmaceutical companies 106
 sharing 74–75, 186
 informed consent 63–66
 injectable medicines 9, 44–45
 inspection 217
 abdomen **227**
 respiratory system **223**
 insurance, professional indemnity 40–41
 interdisciplinary work *see* multidisciplinary
 prescribing teams (MDPTs)
 international normalised ratio (INR) 242, 245
 Internet 107
 intuition 141–142, 143
 definitions 142, **142**
 ion channels 157, 158–159, **161**
 isolation of prescribers 92

 Jehovah's Witness 71
 job satisfaction 4, 281
 'joint vicarious liability' 42
 junior doctors 4, 6
 justice, principle of 80

 Kant, Immanuel 60, 66, 78
 Kent and Medway Strategic Health Authority 287–288

- knowledge
 patients' and consent 66
 patients' and expectations 98
 prescribers' 51, 60, 76, 91, 98
 Knowledge and Skills Framework (KSF) 291
 Kurtz's Enhanced Calgary-Cambridge Guide 116,
 125, 126
- lactation difficulties 257
- languages 100, 270
- lasting power of attorney (LPA) 67, 71–72, 80
- Latin abbreviations 55, 56, **57**
- legal issues and legislation 35–88, 206
 autonomy and consent *see* autonomy; consent
 avoiding litigation 76, 76–77
 doctrine of double effect 81–82
 framework changes for prescribing 36, **37**, 47
 law types 48–49, 49
 negligence and duty of care 50–52
 other countries 35, 280
 prescription writing 52–53
 primary/secondary legislation 48
 professional regulations **37**
 UK laws 47–48
 UK legal system 47–77
 unlicensed/'off-label'/'off-licence'
 medicines 53–54
- licensing of medicines 264
- lidocaine 159
- life-saving treatment, consent and 70, 71
- ligand 156
- ligand-gated ion channels 157, 158
- lipid-soluble drugs 155, 167, 251, 258, 262
- listening 117, 126
- Lister and ors v Hesley Hall Ltd* (2001) 41
- lithium 155, 168, 174, 175, 256
- litigation 236
 avoiding 76, 76–77
- liver disease/impairment, prescribing in 165,
 166, 171, 241–247
 adverse drug reactions 171
 diagnosis 243
 holistic approach 246, **247**
 pharmacology 243–246
 signs and symptoms 242, **242**
- liver function
 drug metabolism 154, 165–166, 244
 tests 242, **242**, 246
- 'living wills' 72
- local anaesthetics 159, 193
- local counter-fraud specialist (LCFS) 46
- location of prescribing consultation 92
- locus of control theory 102
- 'lone workers' 92
- long-term conditions 122, 149, 246
 gypsies and travellers 271
 polypharmacy 166–167
 psychological needs of patients 246
 supplementary prescribing 17–18
- lymph node examination **222**
- Macmillan nurses 286, 287
- management plan *see* clinical management
 plan (CMP)
- management responsibilities 92
- marketing authorisation (MA) 264
- marketing campaigns 106
- MDPT *see* multidisciplinary prescribing teams
 (MDPTs)
- media influence on prescribing 107–108
- Medical Defence Union (MDU) 41, 76
- Medical Devices Agency (MDA) 38
- medic alert bracelets 207
- medical ethics *see* ethics
- medical litigation 50
- medical prescribing, non-medical prescribing
 vs 4–5, 190, 279–280, 282
- medication appropriateness index (MAI) 280
- medication errors 76, 178, 235
- medication review 235–237, 260
- medicine interactions *see* drug interactions
- medicine optimisation 42–43
- Medicines Act (1968) 37, 52, 105
- Medicines Act (1971) 38
- Medicines Act (1992) 1–2
- Medicines and Healthcare Products Regulatory
 Agency (MHRA) 9, 37, 152
 advertising of drugs, control 105
 drug promotion breaches 105
 marketing authorisation 264
 responsibilities 38
 unlicensed medicines 152
 Yellow Card Scheme 38, 173
- Medicines Control Agency (MCA) 38
- medicines management 149, 177–178, 298
- medicines optimisation 178, 235, 236
 principles **236**, 236–237
- men, prescribing for 269
- mens rea 49
- mental capacity 68–69
 adults lacking 61, 65, 67–69, 71–72
 assessment 58, 68–69

- children 70
- consent 61, 62–66, 70
- DH guidance 67–68
- Fraser competence 70
- lasting power of attorney 71–72
- temporary lack of 68
- Mental Capacity Act (2005) 67–68, 69, 71, 80
- mental health/illness 166, 261
 - black/minority ethnic groups 270–271
 - impact of non-medical prescribing 283
 - young people 267
- mental health nurses, lack of prescription
 - writing 286
- mentoring 93, 297
- metabolism of drugs 154, 165, 166
 - children/young people 263
 - ethnicity and 172
 - liver impairment and 165, 166, 171
 - older people 258
 - pregnancy **252**
 - renal impairment 248–249
- metabolites 155, 244, 248–249
- metric system **235**
- Mid Staffordshire NHS Foundation Trust 36
- midwives 22, 266
 - accountability and responsibility 40
 - case study 22, 311
 - education programmes 28
 - MDPTs 189–190
 - professional code of practice 39, **39**
 - supplementary prescribing 17, 21–22
 - V300 prescribing 21–22, 28
- migrants 100
- minority groups 269–271
- Misuse of Drugs Act (1971) 37–38, **38**, 58
- Misuse of Drugs Regulations (2001) 58
- Misuse of Drugs Regulations (2012) 280
- mixing of medicines 152
- Modernising Nursing Careers* (DH 2006) 186
- modification of diet in renal disease (MDRD) 247
- ‘moral rule’ 47
- ‘morals’ *see* ethics
- morbidity, in UK 166
- mouth examination **221**
- Ms B v An NHS Trust* (2002) 67
- multidisciplinary prescribing teams (MDPTs) 93, 183–204
 - allied health professional role 190
 - barriers/challenges 108, 186–187, 201
 - benefits 108, 185–188, 196–197, 201
 - case study 199, 313
 - chemotherapy prescribing 196
 - ‘close communication’ 108
 - commissioning 197–199
 - communication skills 198
 - ‘contact’ professional 199
 - CPD 186–187
 - definition 183–185
 - drivers in/for 184–185, 195, 195
 - dynamics 4
 - education **188**, 200, 201
 - ethos 185–186, 187
 - goals 200
 - health service structures 187
 - holistic approach 194
 - influence on prescribing 108–109
 - information sharing 186
 - lead person 194, 197, 199
 - model for working practice 185–187
 - non-medical 187–188, **188**, 194–197
 - non-medical prescribing lead 194, 279, 287, 292
 - nurse/midwife prescriber roles 189–190
 - organisation **185**, 185–186
 - patient involvement 194, 195, 195
 - pharmacist prescriber roles 188–189
 - physiotherapists 191
 - podiatrists 192–193
 - problems with 198–199
 - radiographers 191–192
 - role of members 186, 188–193, 194, 198–199
 - team members 194, 198, 201
 - terminology confusion 184
- mumps, measles and rubella (MMR)
 - immunisation 108
- narrow therapeutic range 154, 166, 174–177
 - renal impairment and 247
- National Audit Office (NAO) 298
- National Clinical Governance Support Team 288
- national health targets 11
- National Institute for Health and Clinical Excellence (NICE) 42–43, 102–103, 176, 289
- medicines optimisation 235
- psychological needs of patients 246
- renal impairment 247
- National Patients Safety Agency (NPSA) 4
- National Prescribing Centre (NPC) xv, 3, 54, 58
- National Service Frameworks (NSFs) 257, 260, 267, 289
- neck examination **222**
- needs of patients 10–11

- negligence 50–52
 claims for 51
- negotiation, management plan 117, 136
- Neighbour's Inner Consultation 116, 125–126
- neonates 256, 262, 263
- neostigmine 160
- nephrotoxicity 171, 249
- neural tube defects 254
- neurological examination 229–232
- New Consultation model (Pendelton) 116, 125, 126
- New Zealand 281
- NHS
 drug costs 105, 177, 199
 history of prescribing and 278–279
 staff and staff structures 187
 whistleblowing 43
- NHSBSA Prescription Services 279
- NHS Business Services Authority 46
- NHS Constitution 36, 178
- The NHS Plan* (DH 2000) xiv, 277, 290
- NHS Redress Act 2006 51, 52
- NHS Redress Bill (2005) 51
- NHS Redress Scheme 52
- nicotine 156–157
- non-adherence 98
- non-compliance 175, 176, 268
- non-maleficence 79–80
- non-medical prescriber database 291
- non-medical prescribing *see* prescribing (non-medical)
- non-medical prescribing forums 292
- non-medical prescribing lead 194, 279, 287, 292
- non-steroidal anti-inflammatory drugs (NSAIDs) 155, 167, 171, 249, 259
- non-verbal communication 117, 119, **120**
- noradrenaline (NA) 159, 164
- 'normative needs' 10, 11
- nose and sinus examination **220**
- notification of GPs 95
- numeracy 232, 234–235
 assessment 285
 errors/problems 235, 285
 metric system **235**
 skills required **234**
- Nurse Prescribing Bulletin* (NPC 1999) 3
- nurse prescribing/prescribers xiv, 1–2, 19–23
 accountability and responsibility 40
 ageing workforce 286–287
 case studies 311
 CPD *see* continuing professional development (CPD)
- education programmes 19, 20, 21, 28, 286
- extended formulary xiv, 11, 22, 278
- failure to prescribe 190, 279, 286, 291
- formularies xiv, 20, 162
- history 1–2, 3, 277–278
- impact of prescribing on 281–282
- impact on patients 282–283
- independent prescribing xiv, 8–9, **53**, 90
- influences in prescribing 90, 91, 281
- MDPTs 189–190
- negligence and duty of care 51
- number 278, 279
- other countries 280–281
- percent of prescriptions 90
- professional code of practice 39, **39**
- professional regulation 189
- responsibilities and competencies 190
- supplementary prescribing 284
- unlicensed medicines 53–54
 V100 19, 20, 21, 28
 V150 19, 21, 28, 286
 V200 22
 V300 19, 21–22, 28, 286
- 'nursing,' definition 22
- Nursing and Midwifery Council (NMC) 3, 9, 28, 40, 189
 informed consent and 66
 prescribing for children 266
 remote prescribing 44
 transcribing 45
 unlicensed medicine prescribing 54
- off-label medicines 53–54, 264
- off-licence medicines 53–54, 264
- older people 257–262
 adverse drug reactions 171, 172
 autonomy 59
 case studies 305, 306
 co-morbidity and polypharmacy 166–167
 consultations 122, 124
 drugs to be used with caution 259
 holistic approach to prescribing 260–261, **261**
 liver function 171
 narrow therapeutic index drugs 175
 pain assessment 215
 pharmacodynamics 259
 pharmacokinetics 258
 polypharmacy 166–167, 257
 prescribing considerations 260, **261**
 renal function 171, 247–248
- opiates 81, 82, 170, 245
- optometrists 26

- case study 314
- education programmes 26, 29, 192
- independent prescribing **53**, 192
- MDPTs 192
- supplementary prescribing 192
- oral contraceptives 244, 254
- organisational culture 93
- organisational issues, prescribing process 93, 94–95, 287
- impact of non-medical prescribing 279, 283–284
- organisational responsibilities **137**
- organisations, CGC standards and regulations 289
- orthopnoea 208–209
- orthotics 193
- over-the-counter medications 99

- PACT data 292, 293–294
- pain
 - assessment 214–216
 - prescribing for 214, 215–216
- palliative care 170, 287
- palpation 217
 - abdomen **228**
 - respiratory system **223**
- paracetamol 169–170
- paramedics 280
- parenteral formulations, breastfeeding and 256
- parents 70, 267, 268
- paroxysmal nocturnal dyspnoea (PND) 208–209
- partnership 15, 17, 292
- past medical history **130**
- past surgical history **130**
- paternalism 59
- patient(s)
 - acceptability of products 103
 - acceptance of non-medical prescribing 4
 - autonomy *see* autonomy
 - awareness of health behaviour 102
 - case studies 305–309
 - concordance and 176
 - confidentiality 74–75
 - consultations 96–97, 98
 - as consumers 98–99
 - cultural issues 99–101
 - emotions 98
 - empowerment 102
 - expectations 10–11, 97–98, 99, 107, 136
 - harm, prescribing errors 285
 - health beliefs 101–102
 - impact of non-medical prescribing
 - on 282–283
 - influence on prescribing 96–102
 - information, accessibility/
 - confidentiality 74–75, **75**
 - involvement in decision-making 117
 - involvement in MDPTs 194, 195, 195–196
 - knowledge influence on expectations 98
 - language differences 100
 - MDPT benefits for 195–197
 - monitoring after prescribing 205
 - participation and informed consent 66
 - perception of pharmacists 189
 - prescriber relationship *see* prescriber/patient relationship
 - relationship
 - as priority 113, 114
 - safety *see* safety
 - satisfaction with non-medical
 - prescribing 282–283
 - spirituality and religion 100–101
- patient group directions (PGDs) 25, 26–27, 52
 - definition 26
 - indications for 26, 27
 - prescribing differences 26, 37
 - radiographers 191
- patient-specific directions 27
- pattern recognition 140–141, 143, 144
- peak expiratory flow rate (PEFR) 209, **210**
- Pendleton's New Consultation model 116, 125, 126
- percussion 217
 - abdomen **228**
 - notes/sounds **225**
 - respiratory system **224, 225**
- personal characteristics of prescribers 91, 119, 121
- personal development plans 96
- personal information, disclosure 74
- personhood 80
- pharmaceutical companies, influence on
 - prescribing 105–107, 199
- Pharmaceutical Society of Northern Ireland (PSNI) 42
- pharmacists/pharmacist prescribers 2, 23–24, 188–189
 - access, time reduction 94–95
 - accountability and responsibility 40
 - case study 23–24, 312, 313
 - clinical skills 205, 206, 229
 - complexity of role 93
 - confidence 91
 - CPD 295

- pharmacists/pharmacist prescribers (*cont'd*)
- education programmes 29, 188
 - employment and roles 189
 - impact of prescribing on 90, 91, 282
 - implementation of prescribing 91
 - independent prescribing 8–9, 23, 24, **53**, 189
 - influence on prescribing 90, 91, 190
 - in MDPTs, role 188–189
 - monitoring of patients 90
 - negligence and duty of care 51
 - number 279
 - prescribing error detection 285
 - professional code of practice 39, **39**
 - professional regulation 28, 53, 188
 - public perception of 189
 - remuneration 92–93
 - supplementary prescribing 23–24, 189, 282
 - training 188
 - unlicensed medicines 53–54, 152
- pharmacodynamics 150, 156–160, **161–162**
- antihypertensives 163
 - co-morbidity 166
 - diabetic neuropathy management 164
 - impact on patient care 150
 - in liver disease **244**, 245–246
 - medicine interaction 166
 - older people 259
 - renal impairment 249–250
- pharmacokinetics 149–150, 151–156
- antihypertensives 163
 - children/young people 262–265
 - co-morbidity 165, 166
 - diabetic neuropathy management 164
 - drug interactions 168
 - impact on patient care 149–150
 - in liver disease 243–244
 - older people 258
 - in pregnancy 251–252, **252**
 - renal impairment 248–249
- pharmacology 149–150
- formularies and 162–163
 - in liver disease 243–246
 - prescribing in co-morbidity 165–167
 - terms used in 150–160
- pharmacovigilance 99, 173
- pharmacy (P) medicines 37
- pharynx, examination **221**
- phenobarbital sodium 58
- phenytoin 168, 169, 248
- physical examination *see* clinical examination
- physiotherapists *xiv*
- case study 313
 - independent prescribing 25, 191
- MDPTs 191
- supplementary prescribing 18, 24–25, 313
- podiatrists *xiv*
- case study 314
 - for children 193
 - independent prescribing 25, 193
 - MDPTs 192–193
 - supplementary prescribing 19, 24–25
 - training 192–193
- podopaediatrics 193
- polypharmacy 166–167, 257
- adverse drug reactions 171–172
 - case studies 307
- PQRST mnemonic 214
- practitioners, use of term 113
- precedent 47
- pregnancy 251–255
- case study 306, 307
 - holistic approach to prescribing 254, **255**
 - information sources 252–253
 - pharmacokinetics 251–252, **252**
 - physiological changes affecting drugs 251, **252**
 - prescribing considerations **255**
 - prescribing principles 252–253
- prejudices 271
- premature infants 256
- prescriber(s)
- accountability and responsibility 40, 117
 - as advocates 72–73
 - aims for ('good prescribing') 178
 - attributes, therapeutic communication and 117
 - confidence 104
 - impact of prescribing on 281–282
 - influence on prescribing 89–96, 281–282
 - infrastructure for 287
 - institutional/resource factors influencing 92–94
 - intention to prescribe 291
 - maintaining 'own' person 126
 - non-medical/medical relationships 93, 138
 - notification of GPs of prescription 95
 - numbers 278
 - personal characteristics 91, 119, 121
 - pharmaceutical company relationships 106
 - responsibilities **137**
 - role/responsibility changes 92–93
 - vulnerability 92
- prescriber/patient relationship
- consent 64, 65
 - consultation 97, 98, 115, 117
 - consultation models 124, 125

- culture 99–101
- development 119–122
- disclosure of information 74
- ethical principles and consent 64–65
- health beliefs 101
- importance 119
- paternalism and 59
- patient expectations and 97, 98
- prescribing (non-medical) 1, 148
 - ambivalence and success 91
 - benefits 3, 4, 13, 89–90, 185–188, 283
 - challenges 94–95, 206
 - concerns/objections/criticisms 4, 206
 - consultation time 94–95, 97
 - controlled drugs 58
 - culture influencing 99–101
 - debate over 278–280
 - definition 2, 45, 51
 - development xiii–xiv, 277
 - drug companies influencing 105–107, 199
 - ‘dumbing down’ 279
 - expansion/extension (roles) 6, 278, 279
 - external influences 105–110
 - factors influencing practice of 5, 89–112
 - history 1–2, 3, 277, **278**, 278–280
 - increase in 3–4, 90, 278, 284
 - local barriers 93
 - medical prescribing relationship 4–5, 190, 279–280, 282
 - organisational issues 93, 94–95
 - other countries 280–281
 - patient influences on 96–102
 - PGDs differences 26, 37
 - policy, strategies 291–293
 - prescribers influencing success 89–96
 - pressures and responses 29, 29–30, 92–93
 - principles *see* prescribing principles
 - priorities, and role 6
 - product choice influencing 102–103
 - professional issues influencing 95–96
 - unethical 106
- prescribing budget 7
- prescribing errors 4, 55, 76, 285
 - avoiding litigation 76
 - MDPTs and 198
 - numeracy skills 235
 - pharmacists recording 189
 - rate 236
 - transcribing 46
- prescribing principles xv, xv–xvii, 1–2, 3, **3**, 6, 7, 55
 - key principles 3, **3**
 - of pregnancy 252
 - stepwise approach xv, xvi
 - summaries/considerations 30, 83, 109, 145, 179, 202, 238–239, 272, 298
- prescribing pyramid 58
- prescribing rights **53**
 - abuse 43, 60
- prescription(s)
 - dangers of abbreviation use 55–56
 - dosage calculation 234
 - errors 55
 - number 279, 285
 - nurses not writing 190, 279, 286, 287, 291
 - percent written by nurses 90
 - spending on 7, 105, 177, 296
 - time required to generate 94–95
- Prescription Cost Analysis for England 2012* 7
- prescription forms 46
- prescription-only medicine (POM) 37–38, 58
- Prescription Only Medicine Orders 1997 37, 58
- Prescription Only Medicines (Human Use) Order 1997 38
- prescription writing 52–53, 55, 95
 - decision to write 136
 - guidelines **56**
 - lack after qualification 190, 279, 286, 287, 291
 - ‘what strategy’ 54–55
- presenting complaint **128**, 134
- pressures on prescribing 29, 29–30
- primary care, prescribing agreements 93
- primary care trusts (PCTs) 284, 298
- principle of double effect (PDE) 82
- principlism 79–80
- private law 48, 49
- private sector 8–9
- problem-oriented medical record (POMR) 127
- product influence on prescribing 102–104
 - choice 102–103
 - formularies 103–104
- professional ethics 78
- professional framework 36–46, **37**
- professional indemnity 40–41
- professional integrity 80
- professional issues influencing prescribing 95–96
- professional misconduct 43
- professional standards of conduct 39, **39**
- proprietary name prescribing 174–175
- prostaglandins 155
- protein binding 153–154, 244, 248, 256
- psychological needs of patients 246
- Public Concern at Work (PCAW) 43

- public health 9–10
 - policy (UK) 9–10
 - summary/considerations 30, 83, 109, 144, 179, 202, 238–239, 272, 298
- Public Health England 100, 269
- Public Health Outcomes Framework
 - indicators **10**
- public law 48, 49
- pulse 211
- pulse oximetry 209, **209**
- pulse rate 211–213
 - abnormal findings **212**
 - age **212**
- pyrexia 210, 211

- quality 288, 290
- quality-of-life 80

- radial artery, pulse 211
- radiographers
 - case study 313
 - diagnostic 191
 - independent prescribers 191–192
 - MDPTs 191–192
 - supplementary prescribing 24–25, 313
 - therapeutic 191–192
 - training 191
- ramipril 165
- receptors 150, 156–160, 157
 - examples of drug action **161**
- recompense, negligence claims 51
- records
 - access to 19, **75**, 96
 - avoiding litigation 76, 77
 - confidentiality 74, **75**
 - consent 63
 - keeping, principle xvii
 - supplementary prescribing 16, 19
 - transcribing and transposing 45–46
- rectal temperature monitoring 210
- red flags 217, 218
- Re E* (1993) 71
- referral procedures 136–137
- reflective practice 297
- reflexes 229, **233**
 - grading **234**
 - reinforcement 229
- refusal of treatment 58
- regulatory framework 36–46, **37**
- religion 100–101
- 'remedy' (legal) 51
- remote prescribing 13, 44–45
- remuneration 92–93
- renal blood flow 155
- renal function
 - adverse drug reactions and 171
 - age-related decline 166, 167, 258
 - assessment 247–248
 - children 262
 - excretion of drugs 155, 166, 171, 247
 - older people 247–248
 - see also* excretion of drugs
- renal impairment, prescribing in 166, 167, 171, 247–251
 - holistic approach 250, **250**
 - pharmacodynamics 249–250
 - pharmacokinetics 248–249
- repeat prescriptions 94–95
- repetition of tasks 95
- representativeness 140
- research and development costs 106
- respect for autonomy 79
- respect for persons 80
- respiratory rate 207–210
- respiratory system 207–210
 - age 207–209
 - examination 220–221, **223–224**
 - peak flow 209, **210**
 - pulse oximetry 209, **209**
- responsibility 40, 42, 51, 96, 190
 - care for children 266
 - changes for prescribers 92–93, 96
 - increased, impact on prescribers 281–282
 - prescribers, consultations **137**
- review of systems (ROS) **133–134**
- risk assessment 76–77
- risk management 76–77
- Royal Sussex Hospital 43
- rule of double effect (RDE) 82
- R v Cox* (1957) 82
- R v Moor* (2000) 82
- Rx (prescription) 57

- safeguarding 268
- safety 4–5, 29, 113, 114, 148
 - access to information for 94, 96–97
 - agencies/organisations 5
 - children 256, 264, 266
 - clinical decision-making 141
 - impact of prescribing 282
 - Neighbour's Inner Consultation model 125
 - numeracy skills and 235
 - pregnancy 252–253

- prescriber virtues 36
- prescription forms 46
- product choice and 104
- therapeutic communication enhancing 117
- St John's wort 169
- salbutamol 150
- Salmond test* 41
- Saving Lives: Our Healthier Nation* (DH 1999) 13
- school nurses, consent 20
- scope of practice statement 291
- secondary (hospital) care 6, 122, 214, 298
 - prescribing agreements 93
 - prescriptions 294
- secondary legislation 48, 51
- seizures 245–246, 249
- self-awareness of cultural beliefs 100
- self-medication 98–99
- self-monitoring, by men 269
- sharing of information 74–75
- Shipman, Harold 43, 60
- Sidaway v Bethlem Royal Hospital Governors* (1985) 64, 65
- side effects 170
 - adverse drug reactions vs 170
 - consent and 64
 - doctrine of double effect and 82
 - duloxetine 164, 165
 - information for patients 165
 - management 170
 - see also* adverse drug reactions (ADRs)
- signs and symptoms 216
- silence **118**
- simvastatin 171
- Single Competency Framework (NPC 2012) xvii, 13, 296, 297
- sinuses, examination **220**
- social and cultural issues 101–102
 - black/minority ethnic groups 269–270
 - summary/considerations 30, 83, 109, 144, 179, 202, 238–239, 272, 298
 - see also* culture
- Social Care Institute for Excellence (SCIE) 289
- social history (SH) **131–133**
- 'social rule' 47
- sodium ion influx 159
- 'specials' 264
- specificity 156
- sphygmomanometers 213
- spirituality 100–101
- standard operating procedures 292
- standards of conduct, professional 39, **39**
- statutes 47, 48, 88
- sulphasalazine 172
- summaries of product characteristics (SPCs) 162, 243, 253
- summarising, consultation model 125
- summary, history taking **134**
- supervision 292, 297
- supplementary prescribing xiv, 14–19
 - allied health professionals 190
 - benefits 18, 23
 - case study 23–24
 - CMPs *see* clinical management plan (CMP)
 - consent 63, 71
 - definition 14–15
 - DH guidelines 291
 - diagnosis responsibility and 19
 - factors preventing/limiting 284
 - health professionals undertaking 17
 - independent prescribing vs 11–19
 - limitations/concerns 18–19
 - long-term conditions 17–18
 - nurse prescribing 284
 - optometrists 26, 192
 - partnership principle 15, 17
 - pattern recognition 140
 - pharmacists 23–24, 189, 282
 - pharmacokinetics and 152
 - physiotherapists 18, 24–25, 313
 - podiatrists 19, 24–25
 - radiographers 24–25, 313
 - resistance to 17–19
 - termination 17, **17**
- support for prescribers 92, 93, 287–288
- support forums 287, 288
- Sweden 281
- symptom analysis tools **135**
- systolic pressure 213
- tachycardia **212**
- tachypnoea 208
- tacit knowledge 142
- targets of drug action 156–157, 157, **161–162**
- teams *see* multidisciplinary prescribing teams (MDPTs)
- technology, access to printing 95
- teenagers *see* children and young people
- telephone prescribing 44
- temperature (body) 210–211
 - guidelines for monitoring 211, **211**
- temple model (pillars of clinical governance) 288
- teratogenicity and teratogens 251
- tests and investigations 136
- thalidomide 38, 251

- theophylline 174, 175
- theory of reasoned action 101–102
- therapeutic communication 114, 115–124
- children and young people 122, 267
 - clinical decision-making 139, 141
 - consultation 114, 127, 139
 - definition 117
 - enhancing, considerations **122**
 - history taking 127, 139
 - older people 122
 - paralinguistic features 117, **118**
 - relationship development 119–122
 - value 115–124
 - verbal and non-verbal 117, **118**, 119
- therapeutic drug monitoring (TDM) 174
- therapeutic range, narrow *see* narrow therapeutic range
- thiazide-like diuretics 163
- time
- consultations 94–95, 97
 - listening to patients, history taking 126
 - for prescribing 94–95, 97
- tobacco smoking 157–158, 175
- tolcapone 171
- tort law 50
- touch **120**
- transcribing 45–46
- errors 46
- transposing 45–46
- travellers 271
- 'trespass to the person' 61
- tricyclic antidepressants 159, 170, 245, 259
- trust 93, 97, 186
- tuberculosis 171
- tympenic membrane, examination 218–219, **219**
- tympenic membrane temperature 210, **211**
- undiagnosed conditions, independent prescribing 12, 13
- unlicensed medicines 53–54, 152
- allied health professionals 25
 - for children 264
 - nurses 152
 - pharmacists 23, 24, 152
 - supplementary prescribing 25
- unwanted effects of drugs 169–170
- see also* adverse drug reactions (ADRs)
- USA 280, 281
- utilitarianism 78
- V100 prescribing xiv, 19, 20, 21, 28
- V150 prescribing 21, 28, 286
- V200 nurse prescribers 22
- V300 prescribing 21–22, 28, 286
- verbal communication 117, **118**
- vicarious liability 41–42
- virtue ethics 79
- Vistabel® 9, 44
- vital signs 206, 237
- additional 214–216
- voltage-gated channels 159
- voltage-sensitive ion channels 157, 158
- vulnerability in society 184
- vulnerability of prescribers 92
- warfarin 154, 259
- wastage of medicines 178, 284, 298
- water-soluble drugs 244, 248, 249
- 'welfare guardian' 72
- whistleblowing 43
- withholding of information 59
- workload 95
- writing prescriptions *see* prescription writing
- written consent 63
- Yellow Card scheme 38, 173
- 'yellow flags' 218
- young people *see* children and young people